论文部分内容阅读
目的：检测造血细胞肿瘤与非造血细胞肿瘤粒－巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）的表达。方法：测定３０例卵巢恶性肿瘤，２０例卵巢良性肿瘤和４例正常卵巢组织的ＧＭ－ＣＳＦ及ＣＡ－１２５、ＣＥＡ表达情况。结果：ＧＭ－ＣＳＦ只在卵巢恶性肿瘤组织中表达，２０例卵巢良性肿瘤中无一例表达，４例正常卵巢组织对照呈阴性反应。ＣＡ－１２５在卵巢良性及恶性肿瘤组织中均有表达，ＣＥＡ在卵巢恶性肿瘤组织中仅有低表达。９０％卵巢恶性肿瘤组织表达ＧＭ－ＣＳＦ，７７％卵巢恶性肿瘤组织表达ＣＡ－１２５，３５％卵巢良性肿瘤组织表达ＣＡ－１２５，只有１６％卵巢恶性肿瘤组织表达ＣＥＡ。ＧＭ－ＣＳＦ与ＣＡ－１２５结合阳性率可达９７％。结论：ＧＭ－ＣＳＦ可作为卵巢恶性肿瘤标志物。
Objective: To detect the expression of granulocyte-macrophage colony stimulating factor (GM-CSF) in hematopoietic and non-hematopoietic tumors. Methods: The expression of GM-CSF, CA-125 and CEA in 30 cases of ovarian cancer, 20 cases of benign ovarian tumor and 4 cases of normal ovarian tissue were determined. Results: GM-CSF was only expressed in ovarian cancer tissues, no expression in 20 cases of benign ovarian tumors, 4 cases of normal ovarian tissue was negative. CA-125 is expressed in both benign and malignant ovarian tissues and CEA is only low expressed in ovarian malignant tumors. GM-CSF was expressed in 90% of ovarian malignancies, CA-125 in 77% of ovarian cancers, CA-125 in 35% of ovarian benign tumors, and only 16% of ovarian malignancies. GM-CSF and CA-125 binding rate of up to 97%. Conclusion: GM-CSF can be used as a marker of ovarian cancer.